medigraphic.com

2012, Number 2

<< Back

Rev Cub de Toxicol 2012; 1 (2)

Molecular mimicry between major antigens from Neisseria meningitidis B and self-proteins as insufficient condition for triggering early post-vaccination autoimmunity

Batista DA, Tamargo SB, Téllez MB, Fleitas PC, Infante BJF, Portuondo FD, Tamayo IM, Serrano BO, Cabrera BO, Pérez MO, Fresno EM, Sierra GG

Language: English
References: 42
Page:
PDF size: 972.45 Kb.


ABSTRACT

Introduction: the concern that certain vaccines may induce autoimmune disease has been conjectured and one of the proposed mechanisms is molecular mimicry (Mm) between vaccine antigens and self-structures. We investigated if Mm for T epitopes of PorB and other major proteins from Neisseria meningitidis B (NMB), contained in a nanoparticle type cochleate (AIF-nCh), and self-proteins, are able to trigger early autoimmunity reactions in vaccinated C57BL/6 mice.
Methods: Mm between N. meningitidis PorB, HmbR and FrpB, and human/mouse proteins was investigated using the bioinformatic tools: SWISS-PROT/TrEMBL SYFPEITHI and FASTA data bases. C57BL/6 mice were immunized intranasally or intramuscularly with AIF-nCh or vehicle using different treatment protocols. Clinical signs were recorded daily and body weight, every 15 days. Mice were sacrificed on day 60, and full necropsy was performed including microscopic studies, leukocyte count, T CD4+ and TCD8+ cell quantification in local lymph nodules and anti-dsDNA antibody levels by ELISA were determined.
Results: Mm was found in several self-proteins from: blood, liver (including fetal liver), skin, brain, lungs, and testicles (human and mouse). Significant alterations of the endpoints evaluated were not detected in any of the vaccinated mouse, except some lymphoid follicles with germinal centers in the draining lymph node, due to lymphocyte activation induced by the normal immune response to the adjuvant formulation.
Conclusions: despite the existence of Mm between PorB and other proteins from NMB, and self-proteins there was no evidence of organic damage or any type of pathological reaction, in mice vaccinated under our experimental conditions.


REFERENCES

  1. Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. IMAJ. 2004;6:430-2.

  2. Toplak N, Avcin T. Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans. Lupus. 2009;18:1186-91.

  3. Shoenfeld Y, Agmon-Levin N. ASIA'- Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.

  4. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010;9:90-7.

  5. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362:1659-66.

  6. Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmune Rev. 2007;6(5):261-6.

  7. Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J. 1998;12:1253-65.

  8. Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol. 2005;12(3):217-24.

  9. Ryan KR, Patel SD, Stephens LA, Anderton SM. Death, adaptation and regulation: the three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry. J Autoimmun. 2007;29:262-71.

  10. Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci. 2010;118:547-64.

  11. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355-7.

  12. Sierra VG, Campa HC, Valcárcel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14;195-207.

  13. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine. 2009;27S:B42-B50.

  14. Wetzler LM. Innate immune function of the neisserial porinas and the relationship to vaccine adjuvant activity. Future Microbiol. 2010;5:749-58.

  15. Tanabe M, Nimigean CM, Iverson TM. Structural basis for solute transport, nucleotide regulation, and immunological recognition of Neisseria meningitidis PorB. Proc. National Acad. Sci. USA. 2010;107:6811-6.

  16. Jadhav SR, Zheng Y, Garavito MR, Mark Worden R. Functional characterization of PorB class II porines from Neisseria meningitidis using a tethered bilayer lipid membrane. Biosens Bioelectron. 2008;24:837-41.

  17. Massari P, Gunawardana J, Liu X, Wetzler LM. Meningococcal porinas PorB prevents cellular apoptosis in a toll-like receptor 2- and NF--independent manner. Infect Immun. 2010;78:994-1003.

  18. Chiavolini D. Find all citations by this author (default).Or filter your current search Weir S, Murphy JR, Wetzler LM. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensislipopolysaccharide to protect mice against experimental tularemia. Clin Vacc Immunol. 2008;15:1322-9.

  19. Tamargo B, Fleitas C, Infante JF. Evaluación inmunotoxicológica de nuevas formulaciones adyuvantes nanoparticulados sin Al(HO)3 ensayadas como candidatos vacunales contra Neisseria meningitidis. VacciMonitor. 2011;20(Suppl 1):10.

  20. Tamargo B , Rosario LA, Batista N, Arencibia DF, Fernández K, Villegas A,et al. Protección inducida por nanococleatos derivados de proteoliposomas de Leptospira interrogans serovar Canícola. VacciMonitor. 2012;21(1):3-9.

  21. Saleem M, Prince SM, Patel H, Chan H, Feavers IM, Derrick JP. Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis. Acta Cryst. 2012 Feb.; 68(Part 2):231-5. doi: 10.1107/S1744309111056028

  22. Kyle H, Rohde D, Dyer W. Mechanisms of iron acquisition by the human pathogens Neisseria meningitidis and Neisseria gonorrhoeae. Frontiers in Bioscience. 2003 Sept.;8:d1186-218.

  23. Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine. 2005;23:3210-22.

  24. Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: The AS04 experience. Vaccine. 2011;29:4453-9.

  25. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat Biotech. 1984;2:979-84.

  26. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of amphotericin b cochleates against candida albicans infection in a mouse model. Antimicrob Agents Chemother. 2000;14:63-9.

  27. Gizurarson S, Georgsson G, Aggerbeck H, Thorarinsdóttir H, Heron I. Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. Toxicology. 1996;22:61-8.

  28. Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol. 2000;78:5805.

  29. Lang K, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun. 2007;29:206-12.

  30. Brunner R, Jensen-Jarolim E, Schöll I. The ABC of clinical and experimental adjuvants-A brief overview. Immunol Lett. 2010;128:29-35.

  31. Batista Duharte A, Lindblad E, Oviedo E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett. 2011;203:97-105.

  32. Pérez O, Bracho G, Lastre M, Mora N, Campo J del , Gol D, et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol. 2004;82(6):603-10.

  33. Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol. 2001;21:75-85.

  34. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-9.

  35. Dominguez A, Tamayo M, Pérez I, Salas H, Perez O, Batista A. Cytotoxic and genotoxic evaluation of the adjuvant AFCo1 by the sperm head morphology assay in NMRI mice. VacciMonitor. 2009;18:13-7.

  36. Descotes J. Autoimmunity and toxicity testing. Toxicol Lett. 2000;112-113:461-5.

  37. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell. 2007;13:25-35.

  38. Ravel G, Christ M, Horand F, Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link? Toxicology. 2004;196(3):2116.

  39. Waisbren BA. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complementarity in the presence of an immunologic adjuvant and specific HLA patterns. Med Hypotheses. 2008;70(2):346-8.

  40. Rao VP, Kajon AE, Spindler KR, Carayanniotis G. Involvement of epitope mimicry in potentiation but not initiation of autoimmune disease. J Immunol. 1999;162(10):5888- 93.

  41. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis. 2009;9:418-27.

  42. Ochoa RF, Sierra VG, Martínez I, Cuevas I. Prevención de la enfermedad meningocócica. La Habana: Ediciones Finlay ; 2010.




2020     |     www.medigraphic.com